Peptide half-life experiment design: a researcher's guide

Use in silico prediction to triage candidates first, then confirm stability in matrix-matched assays with tightly controlled pre-analytics, and reserve confirmatory in vivo work for leads that survive both filters. The core checklist before you run a single sample: (1) pull existing half-life data from PEPlife and DrugBank; (2) run a sequence-based prediction with a tool like PlifePred or PepMSND to rank candidates; (3) choose your biological matrix deliberately and document the anticoagulant; (4) use protease-inhibitor tubes (P700 or P800) and low-protein-binding consumables from the moment of collection; (5) set timepoints that span at least three half-lives; (6) include stable isotope-labelled spike-in standards and blank matrix controls; (7) fit your decay data to an exponential model and report the confidence interval alongside the half-life estimate. Skipping any one of these steps is where most reproducibility failures originate in peptide half-life research experiment design.

Key takeaways

Pairing in silico triage with matrix-aware, pre-analytically controlled assays is the most efficient path from candidate peptide to a defensible half-life estimate.

Point	Details
Start with in silico triage	Use PEPlife, PlifePred, or PepMSND to rank variants before synthesis; best structure-based models reach R ≈ 0.74 on held-out data.
Match matrix to research question	Fresh whole blood often gives longer half-lives than serum from the same donor; choose matrix deliberately and document the anticoagulant.
Use protease-inhibitor tubes	P700/P800 tubes preserved GLP-1 analogs with half-lives exceeding 72–96 hours versus much shorter values in untreated EDTA samples.
Set timepoints to span three half-lives	Dense early sampling captures the most information; use the in silico estimate to set the timepoint grid before the first run.
Report all pre-analytic conditions	Matrix, anticoagulant, temperature, concentration, and time-to-quench must appear in every methods section for results to be reproducible.
Source peptides with full COA documentation	Peptilab supplies Canadian-manufactured research-grade peptides with batch-specific COAs and purity above 99%, removing a key source of experimental variability.

What do in silico prediction methods actually tell you about peptide half-life?
How does your choice of biological matrix affect measured stability?
How do you design a stepwise experimental protocol for half-life measurement?
Which peptide modifications change half-life, and by how much?
How do you calculate and report peptide half-life correctly?
Which tools and databases should you consult first?
What are the most common pitfalls in peptide stability experiments?
How does Peptilab support reliable half-life experiments for Canadian researchers?
What datasets and validation approaches underpin published half-life models?
Which animal models and cell lines are appropriate for Canadian labs?
What regulatory and safety requirements apply to peptide half-life experiments in Canada?
The case for sequencing computation before experimentation
Peptilab: Canadian-sourced peptides and supplies for stability research
Sources

What do in silico prediction methods actually tell you about peptide half-life?

Computational prediction sits at the front of any rational peptide half-life research experiment design workflow, not because the models are infallible, but because they let you fail cheaply. Running fifty sequence variants through a web server costs nothing; synthesising and assaying them costs weeks and thousands of dollars.

Model classes and what they require

The field has moved through several generations of predictive approaches, and understanding what each requires helps you pick the right tool for your peptide.

Sequence-based QSAR/QSPR models are the oldest and most accessible. They encode each residue as a set of physicochemical descriptors (hydrophobicity, charge, steric bulk) and train a regression or classification model on experimentally measured half-lives. PlifePred, one of the most cited public servers, was trained on several hundred peptides (natural and modified) and achieved a Pearson’s correlation coefficient around 0.74 on held-out data using structure-based descriptors, with mean absolute error indicative of useful but approximate prediction on the log₂ half-life scale. That is a useful signal for ranking, not a precise prediction. The PlifePred paper is explicit about this ceiling.

Descriptor-based ML models using tools like PaDEL-Descriptor extend the feature set to 2D molecular fingerprints and constitutional descriptors, which helps when your peptide carries non-standard modifications that pure sequence encoders cannot represent.

Transformer and graph-based models treat the peptide as a sequence token stream or a molecular graph. Graph attention networks (GAT) and SE(3)-Transformers incorporate 3D geometry, which matters when conformation drives protease recognition. When no experimental structure is available, AlphaFold2 predicted conformations combined with RDKit can supply the 3D features these models need.

Multimodal ensembles represent the current state of the art. PepMSND integrates sequence tokens, 2D graph features, 3D structural transformer outputs, and physicochemical descriptors into a single model. It reported ACC and AUC values in the range of 0.82–0.92 for some experimental conditions, but the PepMSND authors note an accuracy gap of up to approximately 9% between human in vivo and human in vitro predictions. That gap is not a modelling failure; it reflects genuine biological differences between matrices.

Inputs, outputs, and performance at a glance

Model class	Required input	Handles modified residues?	Typical reported metrics	Best suited for
Sequence QSAR/QSPR (PlifePred)	Sequence only	Partially	R ≈ 0.74, MAE ≈ 1.37 (log₂)	Rapid triage of natural peptides
Descriptor-based ML (PaDEL)	Sequence + SMILES	Yes, with SMILES encoding	ACC, AUC (varies by dataset)	Modified peptides, early screening
Transformer / graph (GAT, SE(3))	Sequence + 3D structure	Partially	AUC > 0.80 in some conditions	Conformation-sensitive peptides
Multimodal ensemble (PepMSND)	Sequence + 2D graph + 3D + descriptors	Yes	ACC/AUC 0.82–0.92	High-throughput prioritisation

When predictions help and when they do not

In silico tools are genuinely useful for three tasks: ranking a library of variants before synthesis, scanning for sequence liability hotspots (e.g., Asp-Pro bonds, exposed Lys/Arg for trypsin-like proteases), and generating a prior estimate to inform timepoint selection. They are not a substitute for measurement when you need a half-life value for a regulatory submission, a PK model, or a dose-response calculation.

One important caveat: published models show decreased accuracy for chemically modified peptides unless the modification type is explicitly encoded as a model input. If your peptide is PEGylated, lipidated, or cyclised, check whether the server you are using was trained on modified sequences before trusting its output.

The three public databases worth checking before you build any model or run any assay: PEPlife (experimentally determined half-lives across matrices), DrugBank (approved peptide drugs with PK data), and THPdb (therapeutic peptides with stability annotations). Dataset curation steps for PEPlife commonly filter out sequences outside 5–50 residues, extreme half-life values, and entries lacking explicit experimental conditions. That filtering matters: a model trained on heterogeneous, poorly annotated data will produce heterogeneous, poorly calibrated predictions.

How does your choice of biological matrix affect measured stability?

Matrix selection is one of the most consequential decisions in peptide stability testing, and it is frequently made by default rather than by design. The matrix you choose does not just affect convenience; it changes the proteolytic environment your peptide encounters, which changes the half-life you measure.

Handling fresh whole blood samples in lab

Whole blood vs. plasma vs. serum: what the data show

A 2017 PLOS One study found that peptides were frequently more stable in fresh whole blood than in separated serum or plasma from the same subjects. The explanation is counterintuitive: coagulation and anticoagulant effects alter native protease activity in ex vivo samples. Serum, which is generated by allowing clotting to proceed, releases proteases from platelets and activated coagulation factors. Plasma retains those factors in inactive form, but the anticoagulant you choose (EDTA, heparin, or citrate) introduces its own confounders. EDTA chelates divalent cations and inhibits metallopeptidases; heparin can interfere with certain immunoassays; citrate dilutes the sample by roughly 10%.

The practical implication: if your goal is to predict systemic half-life, a serum-only assay may give you a pessimistic answer. Whole blood or plasma with a physiologically relevant anticoagulant is a better starting point.

Matrix comparison and pre-analytic requirements

Whole blood (fresh): Closest to in vivo proteolytic environment; requires immediate processing; use within 2–4 hours of collection; most relevant for systemic exposure estimates.
EDTA plasma: Inhibits metallopeptidases; good for peptides sensitive to ACE-like enzymes; note that EDTA chelation may artificially extend half-life for some substrates.
Heparin plasma: Preserves broader protease activity than EDTA; preferred when metallopeptidase inhibition would confound results; can interfere with PCR-based downstream assays.
Citrate plasma: Standard for coagulation studies; 10% dilution effect must be corrected; useful when coagulation cascade interactions are part of the research question.
Serum: Highest protease burden due to platelet release; tends to give the shortest measured half-lives; useful as a worst-case screen but not as a sole predictor of in vivo stability.
Pooled commercial plasma/serum: Convenient but introduces batch variability; always characterise the lot before use in a stability study.

Sample handling: the steps that protect your data

Protease-inhibitor tubes such as BD P700 and P800 can extend the apparent ex vivo half-life of GLP-1 and related peptides from minutes to well over 72 hours compared with untreated EDTA samples. That is not an artefact; it is the difference between measuring intrinsic proteolytic susceptibility and measuring how fast your sample degrades on the bench.

Pre-analytic checklist:

Collect into the correct tube for your matrix and anticoagulant choice.
Place samples on ice immediately after collection.
Centrifuge within 30 minutes at 4°C.
Transfer to low-protein-binding polypropylene tubes (Eppendorf LoBind or equivalent).
Add protease inhibitors if the peptide is susceptible to rapid ex vivo degradation.
Store at −80°C; avoid repeated freeze-thaw cycles.
Document time-to-quench for every sample in your methods section.

Pro Tip: Adsorption to labware is a silent killer in peptide assays, particularly below 100 nM. A tutorial review on peptide pre-analytics recommends passivating surfaces with carrier protein or surfactant and verifying extraction recovery with a spiked standard before committing to a full stability run.

How do you design a stepwise experimental protocol for half-life measurement?

The blueprint below is adaptable to most peptide half-life research experiment design scenarios, from a quick in vitro screen to a full non-compartmental PK study.

Timepoint selection

Start by estimating the half-life range from your in silico prediction or from literature analogs. Then set timepoints to cover at least three half-lives, with denser sampling in the first half-life where the decay curve carries the most information.

Estimated half-life range	Recommended timepoints	Minimum sample volume per point
< 30 minutes	0, 5, 10, 20, 30, 45, 60 min	50–100 µL plasma or 200 µL whole blood
30 min – 4 hours	0, 15, 30, 60 min and longer timepoints	100–200 µL plasma
4–24 hours	0, 1, 2, 4, 8 h and longer	200 µL plasma
>24 hours	0, 6, 12, 24, 48, 72, 96 h	200–500 µL plasma

Dose and concentration selection

Keep your working concentration within the linear range of your analytical method and well below the Km of the dominant protease. For screening assays, a starting concentration of 1–10 µM is common; for PK-relevant studies, match the expected in vivo Cmax as closely as your assay sensitivity allows. Saturating protease capacity at high peptide concentrations will artificially extend the measured half-life.

Controls

Every run needs:

Stable spike-in standard: an isotopically labelled version of your peptide (or a structurally similar stable analog) added at a fixed concentration to every sample to correct for matrix effects and extraction variability.
Blank matrix control: matrix processed identically but without peptide, to identify endogenous interferences.
Time-zero (T0) control: peptide added to quenched matrix (e.g., acetonitrile-quenched plasma) to establish 100% recovery.
Enzyme inhibitor control: matrix treated with a broad-spectrum protease inhibitor cocktail to confirm that observed degradation is enzymatic.
Unconstrained sequence control: a scrambled or known-unstable peptide to confirm protease activity in the matrix.

Replicates and statistical planning

For exploratory stability screens, n = 3 independent replicates per timepoint is a practical minimum. For confirmatory PK studies intended to support a regulatory filing or a peer-reviewed methods paper, n ≥ 5 is more defensible, and a power calculation based on expected variance from pilot data should be documented. Censored data points (below the lower limit of quantification) need to be handled explicitly: either impute at LLOQ/2 or use a survival analysis approach, and state your choice in the methods.

A Design of Experiments (DoE) approach using Plackett-Burman or Taguchi designs can efficiently identify which assay variables (pH, temperature, incubation ratio, quench reagent) have the largest effect on measured half-life, especially when sample volumes are limited.

Pre-analytical QC checklist

Confirm peptide identity and purity from the certificate of analysis (COA) before use.
Verify reconstitution solvent compatibility (aqueous buffer vs. DMSO; DMSO above 0.1% can inhibit some proteases).
Check for adsorption: spike a low-concentration standard into your matrix and measure recovery before the full experiment.
Record storage temperature and vial material for every sample.
Document time-to-quench (the interval between sample collection and protease inactivation) for every timepoint.

Which peptide modifications change half-life, and by how much?

Sequence and chemical modifications are the primary engineering levers for tuning proteolytic stability. Each comes with trade-offs that need to be tested, not assumed.

Cyclisation (head-to-tail or side-chain): Removes the free N- and C-termini that exopeptidases attack first; can extend half-life by an order of magnitude for some sequences. Conformational constraint may reduce receptor flexibility, so always retest binding affinity after cyclisation.
D-amino acid substitution: Replaces L-residues at protease recognition sites with their D-enantiomers; highly effective against specific endopeptidases. Substitution at every position is not always tolerated; scan systematically.
N-terminal acetylation: Blocks aminopeptidase cleavage; inexpensive and synthetically straightforward; minimal effect on most receptor interactions.
C-terminal amidation: Blocks carboxypeptidase cleavage; standard modification for many therapeutic peptides; generally well tolerated.
PEGylation: Increases hydrodynamic radius, reducing renal clearance and steric access for proteases; can dramatically extend in vivo half-life. Reduces cell permeability and may lower potency for intracellular targets.
Lipidation (fatty acid conjugation): Drives albumin binding, extending circulation time; used in GLP-1 analogs. Introduces aggregation risk at high concentrations; test solubility in your assay matrix.
Stapling (hydrocarbon or lactam bridges): Stabilises alpha-helical conformation; improves protease resistance and cell penetration for helical peptides. Synthesis is more complex and expensive.
Glycosylation: Bulky sugar moieties sterically block protease access; also modulates immunogenicity. Heterogeneity of glycan patterns complicates analytical characterisation.

Physicochemical sequence features also predict stability without any modification: multivariable regression analyses have linked nonpolar residue fraction, presence of Trp and Tyr, and isoelectric point to serum half-life variance in synthetic peptide libraries. Running this kind of analysis on your sequence before synthesis can identify whether a simple substitution might be enough.

Pro Tip: Before synthesising a panel of modified variants, run an in silico mutational scan using PlifePred or a similar server. Identify positions where a single D-amino acid or N-methylation substitution is predicted to improve stability without disrupting the pharmacophore. Synthesise the top two or three predictions first and use MS fragment mapping to confirm which protease sites were actually blocked.

Scientist validating peptide modifications using LC-MS/MS

The validation step that researchers most often skip: after any stabilising modification, map the metabolic fragments by LC-MS/MS to confirm that you have blocked the dominant cleavage site rather than simply shifted it to a secondary site. A peptide that looks stable in a bulk fluorescence assay may still be generating a potent or toxic fragment.

How do you calculate and report peptide half-life correctly?

The preferred calculation method depends on the data structure. For in vitro stability assays where a single dominant degradation pathway operates, fit the concentration-time data to a monoexponential decay: C(t) = C₀ × e^(−kt), where k is the elimination rate constant and t½ = ln(2)/k. For in vivo PK data with distribution and elimination phases, use non-compartmental analysis (NCA) as the default before committing to a compartmental model.

Stepwise analysis workflow

Raw data QC: Flag and investigate any timepoint where replicate CV exceeds 20%. Check for adsorption artefacts by comparing T0 recovery across replicates.
Normalise to spike-in standard: Divide each measured concentration by the response of the stable isotope-labelled internal standard in the same sample. This corrects for extraction variability and matrix suppression in LC-MS/MS runs.
Plot: Log-linear plot of normalised concentration vs. time. A straight line confirms monoexponential behaviour. Curvature suggests biphasic kinetics or a matrix artefact.
Curve fit: Use weighted least-squares regression (1/C² weighting is standard for LC-MS/MS data). In R, the nls() function or the PKfit package handles this directly. In Python, scipy.optimize.curve_fit with a defined exponential model works well. For NCA, the PKNCA package in R or PKanalix (Lixoft) are widely used in Canadian academic and industry labs.
Extract half-life and report uncertainty: Report t½ with a 95% confidence interval. For small n (fewer than 10 replicates), bootstrap confidence intervals are more reliable than asymptotic standard errors from the fit.
Report experimental conditions explicitly: Matrix, anticoagulant, temperature, peptide concentration, time-to-quench, and analytical method must all appear in the methods section. A literature survey on peptide proteolytic stability found heterogeneous reporting formats across published studies and recommended adoption of standardised t½ reporting to enable cross-study comparisons and model retraining.

For RMSE and model fit quality, report the residual standard error of the fit alongside t½. A good fit on a log-linear scale typically shows residuals randomly distributed around zero; systematic curvature in residuals is a signal to consider a two-compartment or Michaelis-Menten model.

Which tools and databases should you consult first?

These are the resources worth bookmarking at the start of any peptide half-life project. All are freely accessible to Canadian researchers via web browser or open-source download.

PEPlife: The primary public database of experimentally determined peptide half-lives across matrices and species. Use it to check whether your peptide or a close analog has been measured before, and to pull training data for custom models. Access via the BMC Bioinformatics curation paper for dataset provenance details.
DrugBank: Covers approved and investigational peptide drugs with PK parameters including half-life, clearance, and volume of distribution. Useful for benchmarking against clinical data.
THPdb: Therapeutic peptide database with stability and activity annotations; particularly useful for peptides in the 5–50 residue range with known therapeutic targets.
PlifePred web server: Sequence and structure-based half-life prediction; accepts natural and some modified peptides; free web access. Best used for rapid triage of a variant library.
PepMSND: Multimodal predictor integrating sequence, 2D graph, 3D conformation, and physicochemical features. Reported ACC/AUC values of 0.82–0.92 in some conditions. Check the RSC paper for the web server link and input format requirements.
AlphaFold2: Structure prediction for linear peptides when no experimental PDB entry exists. The predicted structure feeds directly into graph-based and 3D-transformer models. Available via the EMBL-EBI web server or locally via the open-source repository.
RDKit: Open-source cheminformatics toolkit for generating 2D molecular descriptors and SMILES-based features for modified peptides. Python-native; runs on any Canadian lab workstation without a licence.
LC-MS vendor software (Sciex Analyst, Waters MassLynx, Thermo Xcalibur): For quantitative half-life assays, your instrument’s native software handles peak integration; export to R or Python for kinetic fitting.

Availability note for Canadian labs: All web servers listed above are accessible without VPN or institutional licence. RDKit, R (with PKNCA and PKfit), and Python (with SciPy and pandas) are free and install on any operating system. AlphaFold2 local installation requires a GPU workstation; the EMBL-EBI web server handles most single-sequence queries without local hardware.

What are the most common pitfalls in peptide stability experiments?

The gap between a well-designed protocol and a reproducible result is almost always pre-analytic or reporting-related, not analytical.

The whole-blood vs. plasma discrepancy

The 2017 PLOS One matrix-effects study is the clearest published demonstration that serum and plasma can give systematically different half-life estimates than fresh whole blood from the same donor. If your peptide shows a short half-life in serum but you are designing for systemic delivery, add a fresh whole-blood validation step before concluding that the peptide is too unstable to advance.

Confounders that researchers underestimate

Sample adsorption: Peptides below 100 nM can lose 30–80% of their mass to plastic surfaces before the first measurement. Use low-binding tubes and verify recovery with every new lot of consumables.
Anticoagulant effects: EDTA extends half-life for metallopeptidase substrates; heparin can interfere with immunoassays; citrate dilutes the sample. Document which anticoagulant you used and why.
Batch variability of pooled serum: Commercial pooled human serum varies in protease activity between lots. Always characterise a new lot with a reference peptide before switching.
Enzyme-only digests: Assays using isolated enzymes (trypsin, chymotrypsin) rather than biological matrices are useful for mechanistic work but do not predict systemic half-life. Do not extrapolate enzyme-only data to in vivo outcomes.
Species differences: Rodent plasma often has higher carboxylesterase and DPP-IV activity than human plasma. A peptide stable in human plasma may degrade rapidly in rat plasma, and vice versa. Always run both species in parallel when the in vivo model is rodent.

Best-practice reporting checklist

Every published or internal stability report should explicitly state:

Matrix (whole blood, EDTA plasma, heparin plasma, serum, etc.)
Anticoagulant and concentration
Temperature during incubation
Peptide concentration and solvent
Time-to-quench (interval from sample collection to protease inactivation)
Analytical method (LC-MS/MS, immunoassay, MALDI-TOF) and LLOQ
Number of replicates and statistical method for half-life calculation

A literature survey on peptide proteolytic stability reporting found that heterogeneous reporting across published studies makes cross-study comparisons and model retraining difficult. Standardised reporting is not bureaucratic overhead; it is what makes your data reusable by the next researcher.

Key finding: Protease-inhibitor tubes (P700/P800) preserved GLP-1 and related peptides with substantially extended half-lives in treated plasma, compared with much shorter half-lives in standard EDTA or untreated samples, demonstrating that pre-analytic tube choice can change a measured half-life by orders of magnitude.

How does Peptilab support reliable half-life experiments for Canadian researchers?

Sourcing peptides and consumables domestically removes a variable that researchers often underestimate: shipping-induced degradation. A peptide that arrives after a week in customs at ambient temperature is not the same material described in the COA.

Peptilab supplies research-grade peptides with batch-specific COAs confirming purity above 99% by HPLC, manufactured and fulfilled within Canada. For half-life experiments specifically, the supplier documentation you need includes:

COA with HPLC purity trace and MS confirmation: Confirms identity and rules out degradation products present before the experiment starts.
Recommended reconstitution solvent and concentration: Critical for avoiding aggregation artefacts that mimic degradation in stability assays.
Storage conditions and stability notes: Tells you whether the peptide is susceptible to freeze-thaw degradation, oxidation, or hydrolysis under your storage conditions.
Batch stability data: Confirms that the lot you received matches the lot used in any published or internal reference data.

Peptilab also supplies laboratory consumables including syringes, bacteriostatic water, and alcohol wipes, reducing the number of suppliers you need to coordinate for a single experiment.

Questions to ask any peptide supplier before a large stability campaign:

Can you provide lot-to-lot comparison data for the last three batches?
What is the recommended maximum number of freeze-thaw cycles?
Has this peptide been tested for adsorption to standard polypropylene tubes?
Is the COA from a third-party analytical laboratory or in-house?

Pro Tip: Request a small pilot lot before committing to a bulk order for a multi-timepoint stability study. Run your T0 recovery check and adsorption screen on the pilot lot. If recovery is below 80%, work with the supplier to adjust the reconstitution protocol before scaling up. Peptilab’s peptide batch consistency guidance covers lot-to-lot QC steps you can adapt for this purpose.

What datasets and validation approaches underpin published half-life models?

Understanding where the training data came from is the fastest way to judge whether a published model applies to your peptide.

PEPlife is the most widely used public source of experimentally determined half-lives. It aggregates data across matrices (human serum, rat plasma, mouse plasma, and others) and sequence types (natural, modified, cyclic). The curation steps applied before model training typically remove sequences outside the 5–50 residue range, entries with extreme or physiologically implausible half-life values, and peptides where the experimental conditions (matrix, temperature, concentration) are not reported. After filtering, usable training sets are often in the low hundreds of entries, which constrains model complexity and generalisation.

External validation on held-out in vivo data is the most demanding test for any predictor. Most published models, including PlifePred, report performance on held-out in vitro data. The PepMSND model is notable for reporting performance separately by species (human vs. rodent) and by experimental environment (in vitro vs. in vivo), which makes its limitations more transparent than models that report a single aggregate metric.

Cross-validation approaches (k-fold, leave-one-out) are standard for small datasets. When the dataset is small enough that a single outlier can shift the reported R by 0.05 or more, bootstrap resampling gives a more honest picture of model uncertainty. When you read a model paper, check whether the reported ACC, AUC, F1, or RMSE comes from a truly held-out test set or from cross-validation on the training data; the distinction matters for how much you trust the prediction.

Species is a persistent confound. Models trained primarily on human serum data perform worse on rodent plasma data, and vice versa. If your in vivo model is rat or mouse, look for a predictor that includes rodent training data or validate the human-trained prediction against a small rodent in vitro dataset before relying on it for experimental planning.

Which animal models and cell lines are appropriate for Canadian labs?

The choice of in vivo model for peptide half-life studies in Canada is governed by both scientific fit and institutional oversight requirements.

Rodent models (rat and mouse) are the most common first-in-vivo step. Sprague-Dawley and Wistar rats are standard for PK studies because their plasma volume allows serial sampling from a single animal, reducing the number of animals needed. C57BL/6 mice are preferred for studies that require transgenic or knockout backgrounds. The key caveat: rodent plasma has higher DPP-IV and carboxylesterase activity than human plasma, which means peptides with DPP-IV-sensitive sequences (e.g., GLP-1 analogs) will show shorter half-lives in rodents than in humans. Plan a parallel human plasma in vitro assay to contextualise the rodent in vivo data.

Non-human primates (NHP) are used when rodent-to-human translation is poor and the peptide is a late-stage candidate. NHP studies in Canada require Animal Use Protocol (AUP) approval from the institutional animal care committee (IACC) under the Canadian Council on Animal Care (CCAC) guidelines. The CCAC’s Guide to the Care and Use of Experimental Animals is the governing document; all protocols must be reviewed and approved before any animal work begins.

Ex vivo human blood and primary cell lines are increasingly used as a bridge between in vitro and in vivo, particularly in Canadian academic labs where NHP access is limited. Fresh human whole blood from healthy donors (collected under ethics board approval) gives a proteolytic environment closer to in vivo than pooled commercial plasma. Primary hepatocytes (human or rat) are the standard cell-based model for metabolic stability when hepatic clearance is a concern.

Cell lines for mechanistic work: Caco-2 monolayers are standard for intestinal permeability and stability; HEK293 and CHO cells are used for receptor-binding assays after stabilising modifications. None of these replace a blood stability assay for systemic half-life estimation, but they add mechanistic resolution.

All animal work in Canada requires CCAC certification of the facility and AUP approval. Ethics board approval is required for human blood collection. Budget 4–8 weeks for protocol review when planning a new in vivo study.

What regulatory and safety requirements apply to peptide half-life experiments in Canada?

Peptide half-life research in Canada sits under several overlapping frameworks depending on the peptide’s origin, the study’s purpose, and whether human samples are involved.

Health Canada oversight: Research-grade peptides used solely for laboratory experiments (not for human administration) are not regulated as drugs under the Food and Drugs Act, provided they are not administered to humans or animals in a clinical context. However, if the research is intended to support a future Investigational New Drug (IND) or Clinical Trial Application (CTA), the data must be generated under Good Laboratory Practice (GLP) principles as defined by Health Canada’s guidance documents.

Controlled substances: Some peptides with opioid, anabolic, or psychoactive activity may be scheduled under the Controlled Drugs and Substances Act (CDSA). Verify the scheduling status of any peptide with opioid receptor activity before ordering or using it in a Canadian lab. A Schedule I or II designation requires a licence from Health Canada’s Office of Controlled Substances.

Biosafety: Experiments using human blood or primary human cells require institutional biosafety committee (IBC) approval and compliance with the Public Health Agency of Canada (PHAC) Human Pathogens and Toxins Act (HPTA). All personnel handling human blood must be trained in biosafety level 2 (BSL-2) procedures.

Ethics: Any study collecting human blood or tissue requires Research Ethics Board (REB) approval under the Tri-Council Policy Statement (TCPS 2). This applies even to ex vivo stability assays using donor blood.

Animal work: As noted above, all animal experiments require CCAC-compliant AUP approval. The Three Rs (Replacement, Reduction, Refinement) must be addressed in the protocol. In vitro and in silico pre-screening, as described throughout this guide, directly supports the Reduction and Replacement requirements.

Waste disposal: Peptide-containing biological waste (blood, plasma, cell culture media) must be inactivated and disposed of according to your institution’s biosafety manual and provincial environmental regulations. Chemical waste from LC-MS/MS solvents (acetonitrile, methanol, formic acid) requires segregated chemical waste disposal.

This is general information about the regulatory framework; confirm current requirements with your institutional biosafety officer, REB, and Health Canada before beginning any new experimental programme.

The case for sequencing computation before experimentation

The conventional framing in peptide pharmacology is that computational prediction is a nice-to-have that you run after you have already decided which peptides to synthesise. That framing is backwards, and the cost of reversing it is low.

Running PlifePred or PepMSND on a 20-member variant library takes an afternoon. The output is not a precise half-life value; it is a ranked list that tells you which three or four sequences are worth the synthesis budget. The models are imperfect, but their errors are not random: they tend to underperform on heavily modified peptides and on sequences outside the training distribution, which is exactly the information you need to decide when to trust the prediction and when to go straight to the bench.

The step that most researchers skip is the whole-blood validation early in the pipeline. Serum stability is faster and cheaper to run, so it gets used as the default screen. But the matrix-effects data make a strong case for adding a single fresh whole-blood timepoint at 30 and 60 minutes alongside your serum screen. It takes one extra tube and one extra injection on the LC-MS/MS, and it catches the peptides that look unstable in serum but are actually fine in a more physiologically relevant environment.

The reporting detail that most often gets cut when a paper is under length pressure is the pre-analytic section: which tube, which anticoagulant, what temperature, how long between collection and quench. That information is not supplementary; it is the data. A half-life measured in EDTA plasma at 37°C with a 45-minute dwell time before quenching is a different number than the same peptide measured in heparin plasma at 37°C quenched immediately. Both are valid measurements of different things. The methods section is where you tell the reader which thing you measured.

Peptilab: Canadian-sourced peptides and supplies for stability research

Designing a rigorous half-life study means controlling every variable you can, and your peptide source is one of them. Peptilab supplies research-grade peptides with batch-specific COAs, confirmed purity above 99%, and domestic Canadian fulfilment that eliminates import delays and cold-chain uncertainty.

Peptilab

For half-life experiment planning, the supplier checklist that protects your data:

COA with HPLC purity trace and MS confirmation for every batch
Recommended reconstitution solvent and maximum concentration to avoid aggregation artefacts
Storage conditions and freeze-thaw stability notes specific to the peptide
Lot-to-lot comparison data before committing to a large experimental campaign
Guaranteed purity above 99% with third-party analytical verification

Browse Peptilab’s research peptide catalogue to find the peptide grade and formulation that fits your assay, or contact the team directly to request batch stability documentation before your next stability campaign.

Sources

These primary references and datasets are the foundation for any peptide half-life research experiment design project. Cite the dataset or model paper in your methods section whenever you use predicted half-lives or draw training data from a public source.

Disclaimer!

Your cart (items: 0)

Peptide half-life experiment design: a researcher’s guide